Test Our Integrated Precision Medicine Approach

Fee-for-service and collaboration via an integrated precision medicine approach

Continuous screening:
Turnaround time starts at day of arrival of compounds at Oncolines and ends with transfer of final report and primary data

Reporting:
Primary data and study report shared via a secured link

Achieve Reproducible Results and Short Timelines

via www.oncolines.com:
Proliferation assays and bioinformatics, drug combination studies and cell-based assays to determine mechanism of action

via www.residencetimer.com:
Biochemical assays to characterise the binding of drug candidates to the target; surface plasmon resonance (SPR) for binding kinetics, kinase activity screening, in vitro proof-of-concept studies